- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
Infection. 2018 Jan 15. doi: 10.1007 / s15010-017-1113-1. [Epub ahead of print]
Influence of antiviral therapy on the liver stiffness in chronic HBV hepatitis.
Rinaldi L1, Ascione A2, Messina V3, Rosato V4, Valente G5, Sangiovanni V6, Zampino R4, Marrone A4, Fontanella L4, de Rosa N7, Orabona P8, Buonomo C8, Chirianni A6, Adinolfi LE4, Piai G5.
Author information
1
Department of Medical, Surgical, Neurological, Metabolic, and Geriatric Sciences, Università degli Studi della Campania "Luigi Vanvitelli", Piazza Miraglia, 80138, Naples, Italy. [email protected].
2
Department of Internal Medicine, Center for Liver Diseases, Ospedale Buon Consiglio Fatebenefratelli, Naples, Italy.
3
Infectious Diseases C.O. Unit, AORN S. Anna and S. Sebastiano, Caserta, Italy.
4
Department of Medical, Surgical, Neurological, Metabolic, and Geriatric Sciences, Università degli Studi della Campania "Luigi Vanvitelli", Piazza Miraglia, 80138, Naples, Italy.
5
Department of Medical Sciences, AORN S.Anna e S. Sebastiano, Caserta, Italy.
6
Department of Infectious Emergencies and Infectious Diseases, Azienda Ospedaliera Dei Colli, Naples, Italy.
7
Department of Diagnostic Service, Azienda Ospedaliera dei Colli, Naples, Italy.
8
Department of Service, AORN S. Anna and S. Sebastiano, Caserta, Italy.
Abstract
PURPOSE:
The aim of this study was to evaluate the effects of antiviral therapy on liver stiffness measurement (LSM).
METHODS:
Two hundred HBV patients were enrolled from four hospital centers in southern Italy; median age was 50.7 (25-75) males were 68%; 171 patients underwent to liver biopsy and 200 patients had LSM at baseline and 189 at the end of follow-up The cutoffs of the LSM, related to the fibrosis stages, were as follows: non-advanced fibrosis ≤ 8.1 kPa and advanced fibrosis ≥ 8.2 Kpa.
RESULTS:
The baseline value of LSM was 14.1 kPa for advanced fibrosis / cirrhosis and 6.9 kPa for non-advanced fibrosis. The treated patients (68% received Entecavir and 32% Tenofovir) showed a decrease in liver stiffness measurement of 1.5 kPa (p <0.001) in non-advanced fibrosis and of 6 kPa (p <0.001) in advanced fibrosis / cirrhosis. In the patients not under antiviral treatment, no significant change of the LSM was logistically binary regression model showed that the only independent factor associated with a significant change in the LSM was the liver stiffness value at baseline (odd ratio 2.855; 95% CI 1.456-5.788; (p = 0.007 ).
CONCLUSION:
Long-term antiviral therapy induced a significant reduction of liver stiffness measurement and this result may be related to the reduction of liver fibrosis.
KEYWORDS:
Antiviral therapy; Chronic hepatitis B; Hepatic fibrosis; Liver stiffness; Transient elastography
PMID:
29335905
DOI:
10.1007 / s15010-017-1113-1
|
|